Clinical Trials Directory

Trials / Completed

CompletedNCT00585936

Imaging Inflammation in Autoimmune Diabetes

Evaluation of Magnetic Nanoparticle Enhanced Imaging in Autoimmune Diabetes

Status
Completed
Phase
Study type
Observational
Enrollment
30 (estimated)
Sponsor
Joslin Diabetes Center · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to determine whether magnetic resonance imaging (MRI) with ferumoxtran-10 can be used to detect changes in the pancreas associated with autoimmune diabetes.

Detailed description

Approximately one million individuals are afflicted with autoimmune Type 1 diabetes mellitus (T1DM) in the United States. This disease results from the autoimmune destruction of the insulin-producing beta-cells of the islets of Langerhans of the pancreas. Initially, diabetes is usually clinically occult with localized pancreatic inflammation characterized by a lymphocytic infiltration of the pancreatic islets, termed insulitis, which leads to beta-cell specific destruction of the islets. This is often followed by the clinically overt phase that ensues when the bulk of beta cells have been destroyed and the pancreas is no longer able to produce sufficient insulin to maintain glycemic control. The purpose of this study is to assess the ability of magnetic resonance imaging with ferumoxtran-10, a functional molecular imaging agent consisting of iron oxide nanoparticles, to detect changes in the pancreas associated with the insulitis of T1DM.

Conditions

Timeline

Start date
2007-09-01
Primary completion
2009-03-01
Completion
2010-03-01
First posted
2008-01-04
Last updated
2011-11-10

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00585936. Inclusion in this directory is not an endorsement.